Cargando…
AKR1D1 is a novel regulator of metabolic phenotype in human hepatocytes and is dysregulated in non-alcoholic fatty liver disease
OBJECTIVE: Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome. Steroid hormones and bile acids are potent regulators of hepatic carbohydrate and lipid metabolism. Steroid 5β-reductase (AKR1D1) is highly expressed in human liver where it inactivates steroid h...
Autores principales: | Nikolaou, Nikolaos, Gathercole, Laura L., Marchand, Lea, Althari, Sara, Dempster, Niall J., Green, Charlotte J., van de Bunt, Martijn, McNeil, Catriona, Arvaniti, Anastasia, Hughes, Beverly A., Sgromo, Bruno, Gillies, Richard S., Marschall, Hanns-Ulrich, Penning, Trevor M., Ryan, John, Arlt, Wiebke, Hodson, Leanne, Tomlinson, Jeremy W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
W.B. Saunders
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6744372/ https://www.ncbi.nlm.nih.gov/pubmed/31330134 http://dx.doi.org/10.1016/j.metabol.2019.153947 |
Ejemplares similares
-
Glucocorticoids regulate AKR1D1 activity in human liver in
vitro and in vivo
por: Nikolaou, Nikolaos, et al.
Publicado: (2020) -
Differential activity and expression of human 5β-reductase (AKR1D1) splice variants
por: Appanna, Nathan, et al.
Publicado: (2021) -
AKR1D1 knockout mice develop a sex-dependent metabolic phenotype
por: Gathercole, Laura L, et al.
Publicado: (2022) -
Optimizing human hepatocyte models for metabolic phenotype and function: effects of treatment with dimethyl sulfoxide (DMSO)
por: Nikolaou, Nikolaos, et al.
Publicado: (2016) -
5α-Reductase Type 2 Regulates Glucocorticoid Action and Metabolic Phenotype in Human Hepatocytes
por: Nasiri, Maryam, et al.
Publicado: (2015)